The US Food and Drug Administration (FDA) has approved Eli Lilly’s orforglipron pill for weight loss, ending Novo Nordisk’s first mover advantage in the US after just three months.
The oral glucagon-like peptide-1 receptor agonist (GLP-1RA) will be branded under the name Foundayo. Lilly expects to launch the drug on its direct-to-consumer channel by 6 April, with retail pharmacy and telehealth provider availability following soon after.
The FDA based its decision on results from the ATTAIN clinical programme, which demonstrated that patients taking the highest dose of Foundayo who remained on treatment lost an average of 12.4% of their body weight.
The approval marks the first new molecular entity (NME) approved under the FDA’s national priority voucher (CNPV) programme. The regulatory pathway was launched by Commissioner Marty Makary to streamline approvals for drugs that showcased a US-centric potential.
GlobalData senior analyst Shehroz Mahmood said: “The FDA's approval of Foundayo (orforglipron) marks a pivotal moment in the oral GLP-1RA obesity space and validates the CNPV programme, which has led to the fastest new molecular entity approval since 2002.”
Oral GLP-1RA rivalry continues
FDA approval for Foundayo brings it into direct competition with Novo’s Wegovy pill (semaglutide), which launched in the US in January 2026. While uptake for Novo’s product has been strong, analysts say market dynamics will hinge on a few key factors.
First, Foundayo’s advantage is that it does not have meal restrictions with administration. Oral Wegovy, on the other hand, must be taken on an empty stomach each morning. Lilly also has the edge in supply chain logistics. As a small molecule, Foundayo has more straightforward manufacturing and scalability processes compared to Wegovy, which is a peptide-based therapy. However, Novo does have the upper hand on the efficacy front. While no direct head-to-head trials have been conducted, the Wegovy pill on average leads to 2.2% better weight loss.
Mahmood commented: “Overall, Lilly faces a fundamentally different competitive challenge than the injectable era, where efficacy superiority enabled Zepbound to overcome Wegovy's first-mover advantage – the oral battleground instead hinges on manufacturing scalability, direct-to-patient marketing reach, and cash-pay pricing strategies, amongst others, each carrying strategic weight.”
The oral GLP-1RA market represents the next battleground for Lilly and Novo. The former won out in the injectable arena owing to higher efficacy and stronger uptake for Mounjaro and Zepbound. Buoyed by obesity drug sales, Lilly’s growth soared by 45% in 2025, contrasting with less lucrative financial results for Novo. Despite reaching the oral obesity market first in the US, Citi analysts forecast that Foundayo’s lack of fasting requirements will place it in pole position to continue Lilly’s cardiometabolic dominance.
Citi analysts said in a research note: “Despite launching second behind Novo's Wegovy pill, we think Foundayo's superior ease-of-use more than offsets its 2.2% efficacy deficit and positions it to eventually capture the lion's share of this rapidly expanding market.”
GlobalData's patient-based forecast predicts that Foundayo will generate $14.8bn in global obesity sales in 2031.
GlobalData is the parent company of Pharmaceutical Technology.
